Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer

Journal of the American Statistical Association

Volumn 107, Issue 498, 2012, Pages 493-508

  Wang, Lu ^a   Rotnitzky, Andrea ^b,c   Lin, Xihong ^c   Millikan, Randall E ^d   Thall, Peter F ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSIDAD TORCUATO DI TELLA   (Argentina)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Causal inference; Efficiency; Informative dropout; Inverse probability weighting; Marginal structural models; Optimal regime; Simultaneous confidence intervals

Indexed keywords

EID: 84864385401     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1080/01621459.2011.641416     Document Type: Article

References (32)

1. Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y. C., DeWit, R., Tannock, I. F., and Eisenberger, M. (2007), "A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis," Clinical Cancer Research, 13(21), 6396-403. [494]
2. Armstrong, A. J., and Eisenberger, M. A. (2006), "Does Gonadotropin-Releasing-Hormone Agonist Therapy for Prostate Cancer Increase the Risk of Fracture?," Natural Clinical Practice Urology, 3(5), 246-7. [494]
3. Bembom, O., and van der Laan, M. (2007), "Commentary: Statistical Methods for Analyzing Sequentially Randomized Trials," Journal of the National Cancer Institute, 99, 1577-1582. [493,494,496,507]
4. Bembom, O., and van der Laan, M. (2008), "Analyzing Sequentially Randomized Trials Based on Causal Effect Models for Realistic Individualized Treatment Rules," Statistics in Medicine, 27(19), 3689-3716. [493,494,495,496,504,507]
5. Dawson, R., and Lavori, P. W. (2012), "Efficient Design and Inference for Multistage Randomized Trials of Individualized Treatment Policies," Biostatistics, 13, 142-152. [507]
6. Gill, R. D. (1989), "Non-and Semi-Parametric Maximum Likelihood Estimators and the vonMises Method," Scandinavian Journal of Statistics, 16, 97-128. [504]
7. Lavori, P., and Dawson, R. (2000), "A Design for Testing Clinical Strategies: Biased Individually TailoredWithin-Subject Randomization," Journal of the Royal Statistical Society, Series A, 163, 29-38. [493]
8. Lavori, P., and Dawson, R. (2004), "Dynamic Treatment Regimes: Practical Design Considerations," Clinical Trials, 1, 9-20. [493]
9. Lunceford, J., Davidian, M., and Tsiatis, A. A. (2002), "Estimation of the Survival Distribution of Treatment Policies in Two-Stage Randomization Designs in Clinical Trials," Biometrics, 58, 48-57. [493]
10. Millikan, R. E., Logothetis, C. J., and Thall, P. F. (2008), "Response: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens," Journal of the National Cancer Institute, 100, 682-683. [494]
11. Murphy, S. A. (2003), "Optimal Dynamic Treatment Regimes (with discussion)," Journal of the Royal Statistical Society, Series B, 65, 331-366. [493,494,495,507]
12. Murphy, S. A. (2005), "An Experimental Design for The Development of Adaptive Treatment Strategies," Statistics in Medicine, 24, 1455-1481. [493,500]
13. Murphy, S. A., van der Laan, Robins, J. M., and CPPRG. (2001), "Marginal Mean Models for Dynamic Treatment Regimes," Journal of the American Statistical Association, 96, 1410-1424. [493]
14. Oetting, A. I., Levy, R. D., Weiss, S. A., and Murphy, S. A. (2011), "Statistical Methodology for a SMART Design in the Development of Adaptive Treatment Strategies," in Causality and Psychopathology: Finding the Determinants of Disorders and their Cures, ed. P. E. Shrout, Arlington, VA: American Psychiatric Publishing, pp. 175-205. [493]
15. Orellana, L., Rotnitzky, A., and Robins, J. (2010), "Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes, Part I: Main Content," International Journal of Biostatistics, 6(2), Article 8. DOI: 10.2202/1557-4679.1200 [493]
16. Robins, J.M. (1986), "ANewApproach to Causal Inference inMortality Studies with Sustained Exposure Periods-Application to Control of the Healthy Survivor Effect," MathematicalModeling, 7, 1393-1512. [493,494,496,499]
17. Robins, J.M. (1987), "Addendum to a New Approach to Causal Inference in Mortality Studies with Sustained Exposure Periods-Application to Control of the Healthy Worker Survivor Effect," Mathematical Modeling, 14, 923-945. [499]
18. Robins, J.M. (1989), "TheAnalysis of Randomized andNonrandomized AIDS Treatment Trials Using a New Approach to Causal Inference in Longitudinal Studies," in Health Service Research Methodology: A Focus on AIDS eds. L. Sechrest, H. Freeman, and A. Mulley, Rockville, MD: U.S. Public Health Service, pp. 113-159. [493]
19. Robins, J.M. (1993), "Analytic Methods for Estimating HIV Treatment and Cofactor Effects," in Methodological issues of AIDS Mental Health Research. eds. D. G. Ostrow, and R. Kessler, New York: Plenum Publishing, pp. 213-290. [493,500]
20. Robins, J.M. (1997), "Causal Inference from Complex Longitudinal Data," in Latent Variable Modeling and Applications to Causality. ed. M. Berkane, New York: Springer Verlag, pp. 69-117. [493]
21. Robins, J.M. (2004), "Optimal Structural Nested Models for Optimal Sequential Decisions," in Proceedings of the Second Seattle Symposium on Biostatistics, eds. D. Y. Lin, and P. Heagerty, New York: Springer, pp. 189-326. [493]
22. Robins, J., Orellana, L., and Rotnitzky, A. (2008), "Estimation and Extrapolation of Optimal Treatment and Testing Strategies," Statistics in Medicine, 27(23), 4678-721. [494]
23. Robins, J. M., Rotnitzky, A., and Zhao, L. P. (1994), "Estimation of Regression-Coefficients When Some Regressors Are Not Always Observed," Journal of the American Statistical Association, 89(427), 846-866. [503]
24. Rubin, D. B. (1978), "Bayesian Inference for Causal Effects: The Role of Randomization," Annals of Statistics, 6, 34-58. [499]
25. Tannock, I. F., DeWit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004), "Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer," New England Journal of Medicine, 351(15), 1502-1512. [494]
26. Thall, P. F., Millikan, R., and Sung, H.-G. (2000), "Evaluating Multiple Treatment Courses in Clinical Trials," Statistics in Medicine, 19, 1011-1028. [493,494,496]
27. Thall, P. F., Logothetis, C., Pagliaro, L., Wen, S., Brown, M. A., Williams, D., and Millikan, R. (2007), "Adaptive Therapy for Androgen Independent Prostate Cancer: A Randomized Selection Trial Including Four Regimens," Journal of the National Cancer Institute, 99, 1613-1622. [493]
28. Thall, P. F., Sung, H.-G, and Estey, E. H. (2002), "Selecting Therapeutic Strategies Based on Efficacy and Death in Multi-Course Clinical Trials," Journal of the American Statistical Association, 97, 29-39. [494,497,507]
29. van der Laan, M. J. (2006), "Causal Effects Models for Intention to Treat and Realistic Individualized Treatment Rules," http://www.bepress.com/ucbbiostat/paper203 [493]
30. van der Laan, M. J., and Petersen, Maya L. (2007), "Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules," The International Journal of Biostatistics, 3 (1), Article 3. DOI: 10.2202/1557-4679.1022. [493,494,496]
31. Wahed, A. S., and Tsiatis, A. A. (2004), "Optimal Estimator for the Survival Distribution and Related Quantities for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials," Biometrics, 60, 124-133. [493]
32. Wahed, A. S., and Tsiatis, A. A. (2006), "Semiparametric Efficient Estimation of Survival Distribution for Treatment Policies in Two-Stage Randomization Designs in Clinical Trials with Censored Data," Biometrika, 93, 163-177. [493]